$Alto Neuroscience (ANRO.US)$ Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial Wednesday, 12th February at 8:03 am – Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker population of ~200 patients in the final analysis sample – – Topline results are expected in mid-2026 – – The company recently reported an estimated preliminary 2024 year-end cash balance of approximately ...
$Alto Neuroscience (ANRO.US)$ Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology Wednesday, 11th December at 8:03 am – Data generated from Alto's precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion – – New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for...
1
1
Report
CNNT
:
Do you have an opinion on how this share will perform in the next few weeks? I have a small position.
$Alto Neuroscience (ANRO.US)$fair price is minmum of 7 dont dump your money if you bought it in expensive price thats silly
3
4
Report
105517956
:
most likely tmr will increase, I bought some options at the lowest point. will up than have to see the then news and analysis before deciding next move.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Alto Neuroscience Stock Forum
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial
Wednesday, 12th February at 8:03 am
– Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker population of ~200 patients in the final analysis sample –
– Topline results are expected in mid-2026 –
– The company recently reported an estimated preliminary 2024 year-end cash balance of approximately ...
Clinical Trial Success: Alto's Novel Depression Treatment Hits Key Milestone in Phase 2b Study
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
Wednesday, 11th December at 8:03 am
– Data generated from Alto's precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion –
– New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for...
<- Blackrock ->
$Alto Neuroscience (ANRO.US)$
sec.gov/Archive...
#myANROanalysis
No comment yet